Congress moves to end tobacco tax loopholes, raising rates across all products
H.R. 1798 — End Tobacco Loopholes Act · Filed by Raja Krishnamoorthi (D-IL) · 3 cosponsors · Introduced Mar 3, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill raises federal excise taxes on tobacco and nicotine products to create tax parity across different forms—cigarettes, cigars, smokeless tobacco, pipe tobacco, roll-your-own tobacco, and newly extracted/synthesized nicotine used in vaping. It increases cigarette taxes substantially (small cigarettes to $100.66 per thousand, large to $211.38 per thousand), applies new taxes to nicotine concentrates at $49.56 per 1,810 milligrams, and indexes all rates to inflation annually starting in 2026. The bill exempts FDA-approved nicotine drugs and includes a floor-stocks tax on inventory held when rates increase, with a $500 per-person credit.
Why we flagged it
The bill's core function is to align excise tax rates across all tobacco and nicotine products to eliminate tax-driven product substitution and raise revenue for public health. It is straightforward tax policy with a clear public-health objective, not a hidden carve-out or subsidy.
What the text implies
- The new tax on extracted/synthesized nicotine may accelerate the shift toward FDA-approved nicotine replacement therapies (NRTs), potentially benefiting pharmaceutical companies producing approved cessation products while raising costs for vaping manufacturers.
- Floor-stocks tax with $500 per-person credit creates a one-time revenue spike but may incentivize rapid inventory liquidation and temporary price spikes at retail, affecting low-income smokers disproportionately in the transition period.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical companies (FDA-approved nicotine replacement therapies); state and local governments (increased tobacco tax revenue); public health organizations (cessation program funding)